Glenn L. Gordon

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

William J. Sandborn, Subrata Ghosh, Julián Panés et al. · Clinical Gastroenterology and Hepatology · 2014 · 295 citations

Inflammation, Chronic Inflammatory Diseases, Anti-inflammatory +9

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 131 citations · Full text

Difference Between Latiglutenase, Villous Atrophy, Clinical Presentation +3

Budesonide Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis

William J. Sandborn, Brian P. Bosworth, Salam Zakko et al. · Gastroenterology · 2015 · 104 citations · Full text

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 89 citations · Full text

Inflammation, Anti-inflammatory, Immunology +7

Briakinumab for Treatment of Crohnʼs Disease

Remo Panaccione, William J. Sandborn, Glenn L. Gordon et al. · Inflammatory Bowel Diseases · 2015 · 76 citations · Full text